ArticleActa parasitologica2025
The VDAC Protein of Rhipicephalus microplus (BmVDAC) Binds To and Enhances the Activation of Plasminogen.
Article in Acta parasitologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeRhipicephalus microplus is a bovine ectoparasite that causes economic losses due to direct damage to the host, the cost of treatments, and the transmission of diverse pathogens. We have previously identified the protein VDAC (BmVDAC) from the midgut of R. microplus. Furthermore, we demonstrated the efficacy of BmVDAC in a bovine vaccination trial. Additionally, BmVDAC interacts with the sexual stages of Babesia bigemina, and its expression increases in ticks during infection with the parasite. Hence, we are interested in studying the function of this protein.
methodsMolecular docking was used to predict that BmVDAC binds to the Kringle 5 (K5) domain of plasminogen, ligand blotting techniques, and inhibition of binding assays with the lysine analog εACA were performed to demonstrate the specificity of the binding.
resultsThe docking analysis predicted the binding of the BmVDAC to the K5 domain, with a lysine participating in this interaction. The ligand blotting and inhibition assays demonstrated the specificity of the binding of the two proteins. Additionally, the results of a plasminogen activation assay showed that BmVDAC increases plasminogen activation.
conclusionThis is the first report of a VDAC protein from a nonmammalian organism that interacts with and enhances the activation of plasminogen. The results indicate that the binding of the two proteins is specific, and the binding of BmVDAC promotes the conversion of plasminogen into active plasmin.
Indexed as
Identifiers
41105371What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.